Arca
Skip to content
Tools
Tools

Gastric cancer

Drug research and approvals for gastric cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 737 studies of gastric cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 30 drug trials for it since 2013, FDA has 15 approved and 91 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 737
  • Trials authorized in Canada: 30
  • FDA orphan approvals: 15
  • EU medicines: 3

Recruiting now

Newest posted first, of 737 recruiting on ClinicalTrials.gov ↗

How its trials ended

2,355 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 371 whose ending is known, 38% met their primary endpoint, 12% missed it and 50% stopped early.

  • Completed, result not reported69630%
  • Ongoing66928%
  • Status unknown61926%
  • Met its primary endpoint1406%
  • Stopped: other or unclear874%
  • Stopped: enrollment or feasibility472%
  • Missed its primary endpoint462%
  • Stopped: sponsor or business decision281%
  • Stopped: lack of efficacy161%
  • Stopped: safety6<1%
  • Stopped: funding1<1%

Trials authorized in Canada

The 10 newest of 30; search them all in Canada trials
Sep 23, 2026A randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab…Cadonilimab (AK104)Akeso Pharma Co., Ltd.Pending
Dec 18, 2025Rosetta gastric-204: a blinded, randomized, phase 2/3 study of pumitamig in combination with chemotherapy versus nivolumab in combination with chemotherapy in…Pumitamig (BMS-986545; BNT327) / Opdivo [nivolumab (BMS-936558)] / Calcium…Bristol-Myers SquibbOngoing
Sep 19, 2025A phase III, multicentre, randomised controlled study of sonesitatug vedotin in combination with fluoropyrimidine with or without rilvegostomig in first-line…Sonesitatug vedotin (AZD0901) / Rilvegostomig (AZD2936)AstraZeneca PharmaceuticalsOngoing
May 30, 2025A phase 3, double-blind, randomized study of zolbetuximab in combination with pembrolizumab and chemotherapy (capox or mfolfox6) in first-line treatment of…Zolbetuximab / PembrolizumabAstellas PharmaPending
Mar 5, 2025A multicenter, randomized, open-label, phase 3 trial of trastuzumab deruxtecan (enhertu®) plus chemotherapy plus or minus pembrolizumab versus chemotherapy…Enhertu / Keytruda / Herzuma / Herceptin / Kanjinti / Trazimera /cisplatin…Daiichi SankyoOngoing
Oct 25, 2024A phase 2 randomized study to evaluate the safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, leucovorin, and budigalimab as…Telisotuzumab adizutecan (ABBV-400) / Budigalimab (ABBV-181) / Fluorouracil /…AbbVieOngoing
Jul 26, 2024A randomized, phase III study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab, chemotherapy, and…Rilvegostomig (AZD2936) / Trastuzumab deruxtecan (t-dxd) / Capecitabine /…AstraZeneca PharmaceuticalsOngoing
Oct 20, 2022A randomized, open-label, multicenter phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in participants with…Zimberelimab (AB122) / Domvanalimab (AB154) / Oxaliplatin / Leucovorin /…Arcus BiosciencesClosed
Nov 16, 2021Pioneering pre- and post-operative integrative care to improve thoracic cancer quality of care: the thoracic peri-operative integrative surgical care…Vitamin DOttawa Hospital Research InstituteOngoing
Aug 12, 2021A randomized trial comparing early local chemoradiation therapy +/- surgery versus systemic therapy for patients with esophageal or gastric cancer with…FluorouracilResearch Institute of The McGill University Health CentreOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 106
Aug 25, 2026TevimbraIn combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment for adults…BeOne Medicines USA, Inc.Approved
Aug 25, 2026Ziihera(1) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, for the first-line treatment of adult…Jazz Pharmaceuticals Ireland LimitedApproved
Nov 25, 2025ImfinziIn combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as neoadjuvant and adjuvant treatment, followed by…AstraZeneca PharmaceuticalsApproved
Dec 26, 2024TevimbraIn combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of adults with unresectable or…BeOne Medicines USA, Inc.Approved
Oct 18, 2024VyloyIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced…Astellas Pharma Global Development Inc.Approved
Nov 16, 2023KeytrudaIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced…MSD International Business GmbHApproved
May 20, 2021OpdivoAdjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who…Bristol-Myers Squibb CompanyApproved
May 5, 2021KeytrudaIn combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with…MSD International Business GmbHApproved
Apr 16, 2021OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic…Bristol-Myers Squibb CompanyApproved
Apr 16, 2021OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic…Bristol-Myers Squibb CompanyApproved
Jan 15, 2021EnhertuTreatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who…Daiichi Sankyo, Inc.Approved
Feb 22, 2019LonsurfLONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously…Taiho Oncology, Inc.Approved
Sep 22, 2017KeytrudaKEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction…MSD International Business GmbHApproved
Nov 5, 2014CyramzaTreatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after…Eli Lilly and CompanyApproved
Apr 21, 2014CyramzaCYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction…Eli Lilly and CompanyApproved

Medicines authorised in the EU

Newest first
Nov 15, 2023HerwendaTrastuzumab · biosimilarSandoz GmbHEMA ↗
Dec 19, 2014CyramzaRamucirumabEli Lilly Nederland B.V.EMA ↗
Mar 14, 2011TeysunoTegafur; gimeracil; oteracilNordic Group B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.